SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Betancourt JR, Maina AW. The institute of medicine report “unequal treatment”: implications for academic health centers. Mt Sinai J Med. 2004; 71: 314321.
  • 2
    Chu KC, Lamar CA, Freeman HP. Racial disparities in breast carcinoma survival rates: separating factors that affect diagnosis from factors that affect treatment. Cancer. 2003; 97: 28532860.
  • 3
    Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005; 55: 1030.
  • 4
    Ward E, Jemal A, Cokkinides V, et al. Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin. 2004; 54: 7893.
  • 5
    Swanson GM, Bailar JC III. Selection and description of cancer clinical trials participants—science or happenstance? Cancer. 2002; 95: 950959.
  • 6
    Monitoring adherence to the NIH policy on the inclusion of women and minorities as subjects in clinical research. Bethesda, MD: National Institutes of Health, 2003.
  • 7
    Sateren WB, Trimble EL, Abrams J, et al. How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J Clin Oncol. 2002; 20: 21092117.
  • 8
    Anonymous. Outreach notebook for the NIH guidelines on inclusion of women and minorities as subjects in clinical research. Bethesda, MD: National Institutes of Health, 1997.
  • 9
    Ford JG, Howerton MW, Bolen S, et al. Knowledge and access to information on recruitment of underrepresented populations to cancer clinical trials. Evid Rep Technol Assess (Summ). 2005; 122: 111.
  • 10
    Brewster WR, Anton-Culver H, Ziogas A, et al. Recruitment strategies for cervical cancer prevention study. Gynecol Oncol. 2002; 85: 250254.
  • 11
    Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Wolmark N. The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial. Clin Breast Cancer. 2002; 3: 153159.
  • 12
    Newman LA, Hurd T, Leitch M, et al. A report on accrual rates for elderly and minority-ethnicity cancer patients to clinical trials of the American College of Surgeons Oncology Group. J Am Coll Surg. 2004; 199: 644651.
  • 13
    Ford ME, Havstad SL, Davis SD. A randomized trial of recruitment methods for older African American men in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial. Clin Trials. 2004; 1: 343351.
  • 14
    Zhu K, Hunter S, Bernard LJ, Payne-Wilks K, Roland CL, Levine RS. Recruiting elderly African-American women in cancer prevention and control studies: a multifaceted approach and its effectiveness. J Natl Med Assoc. 2000; 92: 169175.
  • 15
    Paskett ED, Cooper MR, Stark N, et al. Clinical trial enrollment of rural patients with cancer. Cancer Pract. 2002; 10: 2835.
  • 16
    Thornquist MD, Patrick DL, Omenn GS. Participation and adherence among older men and women recruited to the beta-carotene and retinol efficacy trial (CARET). Gerontologist. 1991; 31: 593597.
  • 17
    Maurer LH, Davis T, Hammond S, Smith E, West P, Doolittle M. Clinical trials in a rural population: professional education aspects. J Cancer Educ. 2001; 16: 8992.
  • 18
    Kaluzny A, Brawley O, Garson-Angert D, et al. Assuring access to state-of-the-art care for U.S. minority populations: the first 2 years of the Minority-Based Community Clinical Oncology Program. J Natl Cancer Inst. 1993; 85: 19451950.
  • 19
    Linnan LA, Emmons KM, Klar N, Fava JL, LaForge RG, Abrams DB. Challenges to improving the impact of worksite cancer prevention programs: comparing reach, enrollment, and attrition using active versus passive recruitment strategies. Ann Behav Med. 2002; 24: 157166.
  • 20
    Kemeny MM, Peterson BL, Kornblith AB, et al. Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol. 2003; 21: 22682275.
  • 21
    Yee KW, Pater JL, Pho L, Zee B, Siu LL. Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier? J Clin Oncol. 2003; 21: 16181623.
  • 22
    Alexander GA, Chu KC, Ho RC. Representation of Asian Americans in clinical cancer trials. Ann Epidemiol. 2000; 10: S61S67.
  • 23
    Goodwin JS, Hunt WC, Humble CG, Key CR, Samet JM. Cancer treatment protocols. Who gets chosen? Arch Intern Med. 1988; 148: 22582260.
  • 24
    Schiffman M, Adrianza ME. ASCUS-LSIL triage study. Design, methods and characteristics of trial participants. Acta Cytol. 2000; 44: 726742.
  • 25
    Benson AB III, Pregler JP, Bean JA, Rademaker AW, Eshler B, Anderson K. Oncologists' reluctance to accrue patients onto clinical trials: an Illinois Cancer Center study. J Clin Oncol. 1991; 9: 20672075.
  • 26
    Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr., Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999; 341: 20612067.
  • 27
    Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol. 2004; 22: 46264631.
  • 28
    Trimble EL, Carter CL, Cain D, Freidlin B, Ungerleider RS, Friedman MA. Representation of older patients in cancer treatment trials. Cancer. 1994; 74: 22082214.
  • 29
    Lewis JH, Kilgore ML, Goldman DP, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol. 2003; 21: 13831389.
  • 30
    Krailo MD, Bernstein L, Sullivan-Halley J, Hammond GD. Patterns of enrollment on cooperative group studies. An analysis of trends from the Los Angeles County Cancer Surveillance Program. Cancer. 1993; 71: 33253330.
  • 31
    Simon MS, Du W, Flaherty L, et al. Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center. J Clin Oncol. 2004; 22: 20462052.
  • 32
    Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004; 291: 27202726.
  • 33
    Tejeda HA, Green SB, Trimble EL, et al. Representation of African-Americans, Hispanics, and whites in National Cancer Institute cancer treatment trials. J Natl Cancer Inst. 1996; 88: 812816.
  • 34
    Hunter CP, Frelick RW, Feldman AR, et al. Selection factors in clinical trials: results from the Community Clinical Oncology Program Physician's Patient Log. Cancer Treat Rep. 1987; 71: 559565.
  • 35
    Berman BA, Wong GC, Bastani R, et al. Household smoking behavior and ETS exposure among children with asthma in low-income, minority households. Addict Behav. 2003; 28: 111128.
  • 36
    Christian MC, Trimble EL. Increasing participation of physicians and patients from underrepresented racial and ethnic groups in National Cancer Institute-sponsored clinical trials. Cancer Epidemiol Biomarkers Prev. 2003; 12: 277s283s.
  • 37
    Moinpour CM, Atkinson JO, Thomas SM, et al. Minority recruitment in the prostate cancer prevention trial. Ann Epidemiol. 2000; 10: S85S91.
  • 38
    Klabunde CN, Springer BC, Butler B, White MS, Atkins J. Factors influencing enrollment in clinical trials for cancer treatment. South Med J. 1999; 92: 11891193.
  • 39
    Hardy CM, Wynn TA, Huckaby F, Lisovicz N, White-Johnson F. African American community health advisors trained as research partners: recruitment and training. Fam Community Health. 2005; 28: 2840.
  • 40
    Bailey JM, Bieniasz ME, Kmak D, Brenner DE, Ruffin MT. Recruitment and retention of economically underserved women to a cervical cancer prevention trial. Appl Nurs Res. 2004; 17: 5560.
  • 41
    Gorelick PB, Harris Y, Burnett B, Bonecutter FJ. The recruitment triangle: reasons why African Americans enroll, refuse to enroll, or voluntarily withdraw from a clinical trial. An interim report from the African-American Antiplatelet Stroke Prevention Study (AAASPS). J Natl Med Assoc. 1998; 90: 141145.
  • 42
    Morse EV, Simon PM, Besch CL, Walker J. Issues of recruitment, retention, and compliance in community-based clinical trials with traditionally underserved populations. Appl Nurs Res. 1995; 8: 814.
  • 43
    Miskimen T, Marin H, Escobar J. Psychopharmacological research ethics: special issues affecting US ethnic minorities. Psychopharmacology (Berl). 2003; 171: 98104.
  • 44
    Corbie-Smith G, Thomas SB, Williams MV, Moody-Ayers S. Attitudes and beliefs of African Americans toward participation in medical research. J Gen Intern Med. 1999; 14: 537546.
  • 45
    Roberson NL. Clinical trial participation. Viewpoints from racial/ethnic groups. Cancer. 1994; 74: 26872691.
  • 46
    Corbie-Smith G, Miller WC, Ransohoff DF. Interpretations of ‘appropriate’ minority inclusion in clinical research. Am J Med. 2004; 116: 249252.
  • 47
    Clarke CA, West DW, Edwards BK, Figgs LW, Kerner J, Schwartz AG. Existing data on breast cancer in African-American women: what we know and what we need to know. Cancer. 2003; 97: 211221.